Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H25ClN2O5.C6H6O3S.2H2O |
| Molecular Weight | 603.082 |
| Optical Activity | ( - ) |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C2=C(COCCN)NC(C)=C([C@@H]2C3=CC=CC=C3Cl)C(=O)OC
InChI
InChIKey=CXOUVSIRCRQEOE-FCQHKQNSSA-N
InChI=1S/C20H25ClN2O5.C6H6O3S.2H2O/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21;7-10(8,9)6-4-2-1-3-5-6;;/h5-8,17,23H,4,9-11,22H2,1-3H3;1-5H,(H,7,8,9);2*1H2/t17-;;;/m0.../s1
| Molecular Formula | C20H25ClN2O5 |
| Molecular Weight | 408.876 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( - ) |
| Molecular Formula | C6H6O3S |
| Molecular Weight | 158.175 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | H2O |
| Molecular Weight | 18.0153 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Levalmodipine (S-amlodipine) is an active enantiomer of amlodipine, a calcium antagonist that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Experimental data suggest that S-amlodipine binds to both dihydropyridine and nondihydropyridine binding sites. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels. S-Amlodipine inhibits calcium ion influx across cell membranes selectively, with a greater effect on vascular smooth muscle cells than on cardiac muscle cells. Enantiomerically pure S-amlodipine is marketed in some countries worldwide, while racemate, containing active S-enantiomer an inactive R-enantiomer is marketed in the USA and indicated for the treatment of hypertension and coronary artery disease.
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17213004/ |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
LEVAMLODIPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2.71 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29559771/ |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: TELMISARTAN |
LEVAMLODIPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
161.7 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17213004/ |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
LEVAMLODIPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
147.43 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29559771/ |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: TELMISARTAN |
LEVAMLODIPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
55 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17213004/ |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
LEVAMLODIPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
45.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29559771/ |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: TELMISARTAN |
LEVAMLODIPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Sources: https://www.mdpi.com/1420-3049/22/11/1879 Page: - |
no [IC50 >50 uM] | |||
Sources: https://www.mdpi.com/1420-3049/22/11/1879 Page: - |
no [IC50 >50 uM] | |||
Sources: https://www.mdpi.com/1420-3049/22/11/1879 Page: - |
no [IC50 >50 uM] | |||
Sources: https://www.mdpi.com/1420-3049/22/11/1879 Page: - |
no [IC50 >50 uM] | |||
Sources: https://www.mdpi.com/1420-3049/22/11/1879 Page: - |
yes [IC50 40.12 uM] | |||
Sources: https://www.mdpi.com/1420-3049/22/11/1879 Page: - |
yes [IC50 9.55 uM] | |||
Sources: https://www.mdpi.com/1420-3049/22/11/1879 Page: - |
yes [Ki 21.45 uM] | |||
Sources: https://www.mdpi.com/1420-3049/22/11/1879 Page: - |
yes [Ki 7.22 uM] | |||
Sources: https://www.mdpi.com/1420-3049/22/11/1879 Page: - |
yes [Ki 8.95 uM] |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Sources: https://dmd.aspetjournals.org/content/42/2/245 Page: - |
unlikely | |||
Sources: https://dmd.aspetjournals.org/content/42/2/245 Page: - |
unlikely | |||
Sources: https://dmd.aspetjournals.org/content/42/2/245 Page: - |
unlikely | |||
Sources: https://dmd.aspetjournals.org/content/42/2/245 Page: - |
unlikely | |||
| yes | ||||
Sources: https://dmd.aspetjournals.org/content/42/2/245 Page: - |
yes | |||
Sources: https://dmd.aspetjournals.org/content/42/2/245 Page: - |
yes | |||
Page: - |
yes | yes (pharmacogenomic study) Comment: Amlodipine pharmacokinetics was affected by the genetic polymorphisms of the ABCB1 gene in humans. Page: - |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 13:17:08 GMT 2025
by
admin
on
Wed Apr 02 13:17:08 GMT 2025
|
| Record UNII |
6WFN2P6FAQ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000174489
Created by
admin on Wed Apr 02 13:17:08 GMT 2025 , Edited by admin on Wed Apr 02 13:17:08 GMT 2025
|
PRIMARY | |||
|
11592465
Created by
admin on Wed Apr 02 13:17:08 GMT 2025 , Edited by admin on Wed Apr 02 13:17:08 GMT 2025
|
PRIMARY | |||
|
6WFN2P6FAQ
Created by
admin on Wed Apr 02 13:17:08 GMT 2025 , Edited by admin on Wed Apr 02 13:17:08 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ANHYDROUS->SOLVATE |
|
||
|
PARENT -> SALT/SOLVATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
|